Clinical trials: Temozolomide
Glioma
Hypofractionated IMRT With Temozolomide for HGG
To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed HGGs after surgery.
- Trial name
- NCT02082119
- Testing
- Hypofractionated IMRT
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Istituto Clinico Humanitas
Glioblastoma, Glioblastoma Multiforme
Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Newly diagnosed glioblastoma (GBM) patients with complete or partial surgical resection who were CMV seropositive patients were eligible to enroll on this trial.
- Trial name
- PERFORMANCE (NCT02864368)
- Testing
- 5-day TMZ, 21-day TMZ, PEP-CMV: Component A
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Eric Thompson, M.D.
Recurrent Glioblastoma
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM.
- Trial name
- NCT03034135
- Testing
- Disulfiram/Copper, Temozolomide (TMZ)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cantex Pharmaceuticals
High Grade Glioma, Ependymoma
HUMC 1612: Optune NovoTTF-200A System
The purpose of this study is to determine if the Optune NovoTTF-200A device can be safely used in combination with chemotherapy in pediatric patients with recurrent high-grade glioma and ependemoma.
- Trial name
- NCT03128047
- Testing
- Optune NovoTTF-200A System
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Hackensack Meridian Health
Malignant Glioma, Grade 4 Malignant Glioma
Bevacizumab Beyond Progression (BBP)
Studies which have separately studied bevacizumab for recurrent gliomas and bevacizumab for newly-diagnosed glioma have shown good results and the regimens have been well-tolerated by patients.
- Conditions
- Malignant Glioma, Grade 4 Malignant Glioma, Glioblastoma, Gliosarcoma
- Trial name
- BBP (NCT01740258)
- Testing
- Radiation Therapy, Temozolomide, Bevacizumab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Duke University
Recurrent Lung Small Cell Carcinoma
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
This randomized phase II trial studies how well temozolomide with or without veliparib works in treating patients with small cell lung cancer that has returned or does not respond to treatment.
- Trial name
- NCT01638546
- Testing
- Laboratory Biomarker Analysis, Temozolomide, Veliparib
- Where
- 14 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, Grade III, Glioblastoma
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
This is a three parallel cohort, open-labeled, non-randomized, multicenter study. All three cohorts will enroll independently.
- Trial name
- STEAM (NCT03224104)
- Testing
- TG02, Radiation Therapy, Temozolomide
- Where
- 10 sites in Austria, France and 3 more
- Volunteers
- 71 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)
The main objective of this study is to investigate whether administration of maintenance temozolomide following standard treatment could possibly prevent or delay the onset of brain metastases in patients with controlled…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Carcinoma, Large Cell, Carcinoma, Squamous Cell
- Trial name
- NCT00632203
- Testing
- Temozolomide
- Volunteers
- 53 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma (Skin)
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as temozolomide, paclitaxel albumin-stabilized nanoparticle formulation, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00626405
- Testing
- bevacizumab, carboplatin, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 259 sites in United States
- Volunteers
- 95 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Neuroendocrine Tumor
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
This research study will test the safety of RAD001 in combination with temozolomide.
- Trial name
- NCT00576680
- Testing
- RAD001, Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Dana-Farber Cancer Institute
Glioblastoma Multiforme, Gliosarcoma
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
The patients eligible for this study are those diagnosed with glioblastoma or gliosarcoma who have recently undergone surgery and who have not been treated with radiation therapy or chemotherapy. This is called a phase II study.
- Trial name
- NCT00187486
- Testing
- Tarceva, Temodar, Radiation Therapy
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of California, San Francisco
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
This protocol will study treatment for Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumor (DSRCT). Participants with ESFT will be divided into two treatment groups, A or B, based on tumor…
- Conditions
- Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT01946529
- Testing
- vincristine, doxorubicin, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Glioblastoma, Astrocytoma, Grade IV
DC Migration Study for Newly-Diagnosed GBM
This randomized phase II study will assess the impact of pre-conditioning on migration and survival among newly diagnosed glioblastoma (GBM) patients who have undergone definitive resection and completed standard temozolomide…
- Conditions
- Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme
- Trial name
- ELEVATE (NCT02366728)
- Testing
- Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Glioblastoma, Gliosarcoma
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly…
- Trial name
- Intellance1 (NCT02573324)
- Testing
- Temozolomide, Depatuxizumab mafodotin, Radiation
- Where
- 212 sites in United States, Argentina and 26 more
- Volunteers
- 691 people
- Sponsor
- AbbVie
Melanoma
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
Temozolomide (also known as TMZ) is a chemotherapy drug given by mouth. It is similar to DTIC, the only FDA-approved chemotherapy for melanoma, but because temozolomide is given by mouth, it can be given daily over a long period…
- Trial name
- NCT00591370
- Testing
- Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Tumors, Spinal Cord Tumors
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.
- Trial name
- NCT00826241
- Testing
- Temozolomide, Lapatinib
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Glioblastoma
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.
- Trial name
- NCT02014844
- Testing
- 250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- ImmunityBio, Inc.
Melanoma
Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
The number of melanoma cases has been steadily increasing over the past few decades. For many patients with metastatic melanoma, there are no effective therapies.
- Trial name
- NCT01009515
- Testing
- Paclitaxel, carboplatin, temozolomide
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- New Mexico Cancer Research Alliance
Glioblastoma
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
This study is a phase I, open label trial to determine the Maximum Tolerated Dose (MTD), safety, pharmacokinetics, and efficacy of BIBW 2992 (an epidermal growth factor receptor(EGFR)inhibitor) to be used in combination with…
- Trial name
- NCT00977431
- Testing
- Temozolomide, Radiotherapy, BIBW2992
- Where
- 5 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Brain Cancer
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
The goal of this clinical research study is to learn if TPI 287 can help to control glioblastoma. The safety of this drug will also be studied.
- Trial name
- NCT01113463
- Testing
- TPI 287
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center